what mg of semaglutide for weight loss Program Sublingual Semaglutide and weight loss

Seki, J

Patients with Type 2 diabetes who have inadequate glycemic control, those with obesity (BMI 30) or overweight individuals with comorbidities, and adults with established cardiovascular disease benefit most from Semaglutide therapy

Evidence Note: NIH literature supports the metabolic and fat-loss benefits of GLP-1 analogs, GHRH/GHRP combinations, and mitochondrial peptides, underscoring their clinical relevance in obesity therapy (NIH)

Both dual and triple agonists are at the early stage of research, but in the future, they may play an important role in the treatment of metabolic disorders, including obesity and PCOS

All patients received 5 mg of oral semaglutide once daily for the first 5 days, then received a dose of 10 mg once daily for the remaining 5 days of the study